Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of TaiMed Biologics.

    Client Virtual Booth

    TAIMED BIOLOGICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    TaiMed Biologics
    Taiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    3F., No.607, Ruiguang Rd., Neihu Dist., Taipei City 11492
    Telephone
    Telephone
    886-2-26580058
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.taimedbiologics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region

    Details:

    Under the terms of this agreement, AcedrA will register, promote and commercialize Trogarzo (Ibalizumab-uiyk), a CD4-directed post-attachment HIV-1 inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, in the MENA region.


    Lead Product(s): Ibalisumab

    Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: AcedrA BioPharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement March 18, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment

    Details:

    TMB-365/380 monoclonal antibodies is an ultra-long-acting new drug combination, which is investigated for the treatment of human immunodeficiency virus infection.


    Lead Product(s): TMB-365,TMB-380

    Therapeutic Area: Infections and Infectious Diseases Product Name: TMB-365

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 16, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search